JACKSONVILLE, Fla., October 23, 2024--United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, and its subsidiary Lung Bioengineering Inc. (LBE) announced that the 500th lung ...

United Therapeutics’ key phase III programs include Tyvaso in patients with various forms of chronic fibrosing interstitial lung disease (TETON studies) and oral ralinepag in PAH indications ...

United Therapeutics’ UTHR fourth-quarter 2024 ... for PAH and pulmonary hypertension associated with interstitial lung disease (PH-ILD) indications. Tyvaso DPI recorded sales of $273.2 million ...